Clinical Trial Update: Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating sitravatinib in combination with nivolumab versus docetaxel in advanced/metastatic non-squamous non-small cell lung cancer has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GAVRETO (pralsetinib)
• OPDIVO (nivolumab)
• Taxotere (docetaxel)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-06-25